GLP-1 Drugs Like Ozempic May Boost Fertility in Women

A new peer-reviewed study published in Reproductive Biology and Endocrinology suggests that semaglutide — the active ingredient in Ozempic and Wegovy — may improve fertility outcomes in women with overweight or obesity who are struggling to conceive. The finding adds a potentially significant dimension to how GLP-1 medications are understood beyond weight loss and blood sugar control.

What the Research Found

The study examined the impact of semaglutide pretreatment on reproductive outcomes in women with overweight and obesity who had infertility. Conducted as a real-world multicenter cohort study, the research drew on data from multiple clinical sites, lending it broader applicability than a single-center trial.

The study's design — real-world and multicenter — means the findings reflect actual patient experiences rather than tightly controlled experimental conditions, which can make results more relevant to everyday clinical practice. However, it also means other variables may have influenced outcomes.

Why This Matters for GLP-1 Patients

For women with overweight or obesity who are trying to conceive, this research raises important possibilities. Excess body weight is already known to affect hormonal balance, ovulation, and overall reproductive health. GLP-1 receptor agonists like semaglutide drive meaningful weight loss and improve metabolic markers, which may in turn create a more favorable environment for conception.

It is worth noting that semaglutide is not currently approved as a fertility treatment. Ozempic is FDA-approved for type 2 diabetes management, while Wegovy is approved for chronic weight management — neither carries an indication for improving fertility. Women who are pregnant or planning to become pregnant are currently advised to discontinue semaglutide, as safety data in pregnancy remains limited.

What Patients Should Keep in Mind

While the study's publication in a peer-reviewed journal is a meaningful step, one cohort study is not enough to change prescribing guidelines or clinical recommendations. Larger randomized controlled trials would be needed before semaglutide could be formally considered as part of a fertility treatment protocol.

Women currently on Ozempic or Wegovy who are considering pregnancy should have a direct conversation with their prescriber. Stopping the medication before attempting conception is the current standard guidance, and this new research does not override that recommendation.

What to Watch Next

This study is likely to prompt further investigation into GLP-1 drugs and reproductive health. Researchers and fertility specialists will be watching for follow-up studies that can confirm these findings, identify which patient populations benefit most, and clarify the safest timing for stopping semaglutide before attempting conception. As GLP-1 medications continue to be studied across a wide range of conditions, reproductive outcomes are becoming an increasingly active area of research.

Frequently Asked Questions

As always, any decisions about starting, continuing, or stopping a GLP-1 medication — especially in the context of fertility or pregnancy planning — should be made in close consultation with your prescriber or a qualified specialist who knows your full medical history.